Purine Nucleoside Phosphorylase mediated molecular chemotherapy and conventional chemotherapy: A tangible union against chemoresistant cancer

BMC Cancer

Volumn 11, Issue , 2011, Pages

  Singh, Preetinder P ^a,c   Joshi, Swapna ^a,b   Russell, Pamela J ^a,d,e   Nair, Sham ^f   Khatri, Aparajita ^a,b  

^a PRINCE OF WALES HOSPITAL   (Australia)

^b UNIVERSITY OF NEW SOUTH WALES   (Australia)

^c MONASH MEDICAL CENTRE   (Australia)

^d Translational Research Institute   (Australia)

^e QUEENSLAND UNIVERSITY OF TECHNOLOGY   (Australia)

^f MACQUARIE UNIVERSITY   (Australia)

Author keywords

Cancer; Chemotherapy; Fludarabine Phosphate (Fludara); Gene directed enzyme prodrug therapy (GDEPT); Molecular chemotherapy; Ovarian cancer; Purine nucleoside phosphorylase (PNP)

Indexed keywords

AGRIN; CADHERIN; CADHERIN 6; CARBOPLATIN; CASPASE 7; CASPASE 9; CYTOKERATIN 5; DESMOPLAKIN; DIHYDROLIPOAMIDE SUCCINYLTRANSFERASE; DNA DIRECTED RNA POLYMERASE; DOCETAXEL; DYNACTIN; EPOXIDE HYDROLASE; FILAGGRIN; GUANINE NUCLEOTIDE BINDING PROTEIN; INHIBITOR OF APOPTOSIS PROTEIN; INITIATION FACTOR 3; INSULINASE; KARYOPHERIN ALPHA; MITOCHONDRIAL PROTEIN; NICOTINAMIDE ADENINE DINUCLEOTIDE ADENOSINE DIPHOSPHATE RIBOSYLTRANSFERASE; PLAKOGLOBIN; PROTEIN BAX; PROTEIN BCL 2; PURINE NUCLEOSIDE PHOSPHORYLASE; RIBOSOMAL PROTEIN L4; RIBOSOME PROTEIN; SURVIVIN; TUMOR SUPPRESSOR PROTEIN; UNCLASSIFIED DRUG; ANTINEOPLASTIC AGENT; PRODRUG; TAXOID;

APOPTOSIS; ARTICLE; BYSTANDER EFFECT; CANCER CELL CULTURE; CANCER INHIBITION; CELL ASSAY; CELL CYCLE; CELL VIABILITY; CHEMOSENSITIVITY; CONCENTRATION RESPONSE; CONTROLLED STUDY; DOWN REGULATION; DRUG ANTAGONISM; DRUG CYTOTOXICITY; DRUG POTENTIATION; FEMALE; FLOW CYTOMETRY; GENE DIRECTED ENZYME PRODRUG THERAPY; HUMAN; HUMAN CELL; IN VITRO STUDY; MULTIDRUG RESISTANCE; OVARY CANCER; PROTEIN EXPRESSION; PROTEOMICS; STATISTICAL ANALYSIS; WESTERN BLOTTING; ADENOVIRUS; CELL SURVIVAL; DRUG EFFECT; DRUG RESISTANCE; GENE EXPRESSION PROFILING; GENE EXPRESSION REGULATION; GENE THERAPY; GENE VECTOR; GENETIC TRANSDUCTION; GENETICS; METABOLISM; OVARY TUMOR; TUMOR CELL LINE;

ADENOVIRIDAE; ANTINEOPLASTIC AGENTS; APOPTOSIS; BYSTANDER EFFECT; CARBOPLATIN; CELL CYCLE; CELL LINE, TUMOR; CELL SURVIVAL; DRUG RESISTANCE, NEOPLASM; DRUG SYNERGISM; FEMALE; GENE EXPRESSION PROFILING; GENE EXPRESSION REGULATION; GENE THERAPY; GENETIC VECTORS; HUMANS; OVARIAN NEOPLASMS; PRODRUGS; PROTEOMICS; PURINE-NUCLEOSIDE PHOSPHORYLASE; TAXOIDS; TRANSDUCTION, GENETIC;

EID: 80052024774     PISSN: None     EISSN: 14712407     Source Type: Journal    
DOI: 10.1186/1471-2407-11-368     Document Type: Article

References (48)

1. Russell PJ, Khatri A. Novel gene-directed enzyme prodrug therapies against prostate cancer. Expert Opin Investig Drugs 2006, 15:947-961. 10.1517/13543784.15.8.947, 16859396.
2. Nawa A, Tanino T, Luo C, Iwaki M, Kajiyama H, Shibata K, Yamamoto E, Ino K, Nishiyama Y, Kikkawa F. Gene directed enzyme prodrug therapy for ovarian cancer: could GDEPT become a promising treatment against ovarian cancer?. Anticancer Agents Med Chem 2008, 8:232-239. 10.2174/187152008783497000, 18288924.
3. Singh P, Yam M, Russell PJ, Khatri A. Molecular and traditional chemotherapy: a united front against prostate cancer. Cancer Lett 2010, 293:1-14. 10.1016/j.canlet.2009.11.019, 20117879.
4. Vasey PA. Ovarian cancer: front-line standard treatment in 2008. Ann Oncol 2008, 19(Suppl 7):vii61-66.
5. Han LY, Kipps E, Kaye SB. Current treatment and clinical trials in ovarian cancer. Expert Opin Investig Drugs 2010, 19:521-534. 10.1517/13543781003647966, 20367193.
6. Zhang Y, Parker WB, Sorscher EJ, Ealick SE. PNP anticancer gene therapy. Curr Top Med Chem 2005, 5:1259-1274. 10.2174/156802605774463105, 16305530.
7. Parker WB, Allan PW, Shaddix SC, Rose LM, Speegle HF, Gillespie GY, Bennett LL. Metabolism and metabolic actions of 6-methylpurine and 2-fluoroadenine in human cells. Biochem Pharmacol 1998, 55:1673-1681. 10.1016/S0006-2952(98)00034-3, 9634004.
8. Sorscher EJ, Peng S, Bebok Z, Allan PW, Bennett LL, Parker WB. Tumor cell bystander killing in colonic carcinoma utilizing the Escherichia coli DeoD gene to generate toxic purines. Gene Ther 1994, 1:233-238.
9. Hughes BW, King SA, Allan PW, Parker WB, Sorscher EJ. Cell to cell contact is not required for bystander cell killing by Escherichia coli purine nucleoside phosphorylase. J Biol Chem 1998, 273:2322-2328. 10.1074/jbc.273.4.2322, 9442077.
10. Gadi VK, Alexander SD, Kudlow JE, Allan P, Parker WB, Sorscher EJ. In vivo sensitization of ovarian tumors to chemotherapy by expression of E. coli purine nucleoside phosphorylase in a small fraction of cells. Gene Ther 2000, 7:1738-1743. 10.1038/sj.gt.3301286, 11083495.
11. Martiniello-Wilks R, Wang XY, Voeks DJ, Dane A, Shaw JM, Mortensen E, Both GW, Russell PJ. Purine nucleoside phosphorylase and fludarabine phosphate gene-directed enzyme prodrug therapy suppresses primary tumour growth and pseudo-metastases in a mouse model of prostate cancer. J Gene Med 2004, 6:1343-1357. 10.1002/jgm.629, 15493036.
12. Hong JS, Waud WR, Levasseur DN, Townes TM, Wen H, McPherson SA, Moore BA, Bebok Z, Allan PW, Secrist JA, et al. Excellent in vivo bystander activity of fludarabine phosphate against human glioma xenografts that express the escherichia coli purine nucleoside phosphorylase gene. Cancer Res 2004, 64:6610-6615. 10.1158/0008-5472.CAN-04-0012, 15374975.
13. Lockett LJ, Molloy PL, Russell PJ, Both GW. Relative efficiency of tumor cell killing in vitro by two enzyme-prodrug systems delivered by identical adenovirus vectors. Clin Cancer Res 1997, 3:2075-2080.
14. Mohr L, Shankara S, Yoon SK, Krohne TU, Geissler M, Roberts B, Blum HE, Wands JR. Gene therapy of hepatocellular carcinoma in vitro and in vivo in nude mice by adenoviral transfer of the Escherichia coli purine nucleoside phosphorylase gene. Hepatology 2000, 31:606-614. 10.1002/hep.510310310, 10706550.
15. Bzowska A, Kulikowska E, Shugar D. Properties of purine nucleoside phosphorylase (PNP) of mammalian and bacterial origin. Z Naturforsch [C] 1990, 45:59-70.
16. du Bois A, Luck HJ, Meier W, Adams HP, Mobus V, Costa S, Bauknecht T, Richter B, Warm M, Schroder W, et al. A randomized clinical trial of cisplatin/paclitaxel versus carboplatin/paclitaxel as first-line treatment of ovarian cancer. J Natl Cancer Inst 2003, 95:1320-1329.
17. Ozols RF, Bundy BN, Greer BE, Fowler JM, Clarke-Pearson D, Burger RA, Mannel RS, DeGeest K, Hartenbach EM, Baergen R. Phase III trial of carboplatin and paclitaxel compared with cisplatin and paclitaxel in patients with optimally resected stage III ovarian cancer: a Gynecologic Oncology Group study. J Clin Oncol 2003, 21:3194-3200. 10.1200/JCO.2003.02.153, 12860964.
18. Oishi T, Kigawa J, Fujiwara K, Fujiwara M, Numa F, Aotani E, Katsumata N, Kohno I, Kato H, Terakawa N. A feasibility study on biweekly administration of docetaxel for patients with recurrent ovarian cancer. Gynecol Oncol 2003, 90:421-424. 10.1016/S0090-8258(03)00322-6, 12893211.
19. Rose PG, Blessing JA, Ball HG, Hoffman J, Warshal D, DeGeest K, Moore DH. A phase II study of docetaxel in paclitaxel-resistant ovarian and peritoneal carcinoma: a Gynecologic Oncology Group study. Gynecol Oncol 2003, 88:130-135. 10.1016/S0090-8258(02)00091-4, 12586591.
20. Markman M. Taxanes in the management of gynecologic malignancies. Expert Rev Anticancer Ther 2008, 8:219-226. 10.1586/14737140.8.2.219, 18279063.
21. Engblom P, Rantanen V, Kulmala J, Grenman S. Carboplatin-paclitaxel- and carboplatin-docetaxel-induced cytotoxic effect in epithelial ovarian carcinoma in vitro. Cancer 1999, 86:2066-2073. 10.1002/(SICI)1097-0142(19991115)86:10<2066::AID-CNCR26>3.0.CO;2-1, 10570433.
22. Vasey PA, Jayson GC, Gordon A, Gabra H, Coleman R, Atkinson R, Parkin D, Paul J, Hay A, Kaye SB. Phase III randomized trial of docetaxel-carboplatin versus paclitaxel-carboplatin as first-line chemotherapy for ovarian carcinoma. J Natl Cancer Inst 2004, 96:1682-1691. 10.1093/jnci/djh323, 15547181.
23. Escobar PF, Rose PG. Docetaxel in ovarian cancer. Expert Opin Pharmacother 2005, 6:2719-2726. 10.1517/14656566.6.15.2719, 16316310.
24. MacKenzie SH, Clark AC. Targeting cell death in tumors by activating caspases. Curr Cancer Drug Targets 2008, 8:98-109. 10.2174/156800908783769391, 3119715, 18336192.
25. LaCasse EC, Mahoney DJ, Cheung HH, Plenchette S, Baird S, Korneluk RG. IAP-targeted therapies for cancer. Oncogene 2008, 27:6252-6275. 10.1038/onc.2008.302, 18931692.
26. Voeks D, Martiniello-Wilks R, Madden V, Smith K, Bennetts E, Both GW, Russell PJ. Gene therapy for prostate cancer delivered by ovine adenovirus and mediated by purine nucleoside phosphorylase and fludarabine in mouse models. Gene Ther 2002, 9:759-768. 10.1038/sj.gt.3301698, 12040457.
27. Chou TC, Talalay P. Quantitative analysis of dose-effect relationships: the combined effects of multiple drugs or enzyme inhibitors. Adv Enzyme Regul 1984, 22:27-55.
28. Chou TC, Hayball MP. Calcusyn: Windows software for dose effect analysis. 1996, Cambridge (England): Anonymous Biosoft.
29. Chou J, Chou TC. Computerized simulation of dose reduction index (DRI) in synergistic drug combinations. Pharmacologist 1988, 30.
30. Towbin H, Staehelin T, Gordon J. Electrophoretic transfer of proteins from polyacrylamide gels to nitrocellulose sheets: procedure and some applications. Proc Natl Acad Sci USA 1979, 76:4350-4354. 10.1073/pnas.76.9.4350, 411572, 388439.
31. Shevchenko A, Wilm M, Vorm O, Mann M. Mass spectrometric sequencing of proteins silver-stained polyacrylamide gels. Anal Chem 1996, 68:850-858. 10.1021/ac950914h, 8779443.
32. See HT, Freedman RS, Kudelka AP, Burke TW, Gershenson DM, Tangjitgamol S, Kavanagh JJ. Retrospective review: re-treatment of patients with ovarian cancer with carboplatin after platinum resistance. Int J Gynecol Cancer 2005, 15:209-216. 10.1111/j.1525-1438.2005.15205.x, 15823101.
33. Smith JA, Ngo H, Martin MC, Wolf JK. An evaluation of cytotoxicity of the taxane and platinum agents combination treatment in a panel of human ovarian carcinoma cell lines. Gynecol Oncol 2005, 98:141-145. 10.1016/j.ygyno.2005.02.006, 15963813.
34. Konstantinopoulos PA, Fountzilas E, Pillay K, Zerbini LF, Libermann TA, Cannistra SA, Spentzos D. Carboplatin-induced gene expression changes in vitro are prognostic of survival in epithelial ovarian cancer. BMC Med Genomics 2008, 1:59. 10.1186/1755-8794-1-59, 2613398, 19038057.
35. Fabbri F, Carloni S, Brigliadori G, Zoli W, Lapalombella R, Marini M. Sequential events of apoptosis involving docetaxel, a microtubule-interfering agent: a cytometric study. BMC Cell Biol 2006, 7:6. 10.1186/1471-2121-7-6, 1413524, 16438719.
36. Nguyen HN, Sevin BU, Averette HE, Perras J, Ramos R, Donato D, Ochiai K, Penalver M. Cell cycle perturbations of platinum derivatives on two ovarian cancer cell lines. Cancer Invest 1993, 11:264-275. 10.3109/07357909309024851, 8485649.
37. Boehrer S, Nowak D, Hoelzer D, Mitrou PS, Chow KU. Novel agents aiming at specific molecular targets increase chemosensitivity and overcome chemoresistance in hematopoietic malignancies. Curr Pharm Des 2006, 12:111-128. 10.2174/138161206780574588, 16454729.
38. Eastman A, Rigas JR. Modulation of apoptosis signaling pathways and cell cycle regulation. Semin Oncol 1999, 26:7-16. discussion 41-12.
39. Oliver FJ, de la Rubia G, Rolli V, Ruiz-Ruiz MC, de Murcia G, Murcia JM. Importance of poly(ADP-ribose) polymerase and its cleavage in apoptosis. Lesson from an uncleavable mutant. J Biol Chem 1998, 273:33533-33539. 10.1074/jbc.273.50.33533, 9837934.
40. Chou TC. Theoretical basis, experimental design, and computerized simulation of synergism and antagonism in drug combination studies. Pharmacol Rev 2006, 58:621-681. 10.1124/pr.58.3.10, 16968952.
41. Kaye SB, Vasey PA. Docetaxel in ovarian cancer: phase III perspectives and future development. Semin Oncol 2002, 29:22-27.
42. Markman M. Managing taxane toxicities. Support Care Cancer 2003, 11:144-147.
43. Wahl AF, Donaldson KL, Fairchild C, Lee FY, Foster SA, Demers GW, Galloway DA. Loss of normal p53 function confers sensitization to Taxol by increasing G2/M arrest and apoptosis. Nat Med 1996, 2:72-79. 10.1038/nm0196-72, 8564846.
44. Li Y, Okegawa T, Lombardi DP, Frenkel EP, Hsieh JT. Enhanced transgene expression in androgen independent prostate cancer gene therapy by taxane chemotherapeutic agents. J Urol 2002, 167:339-346. 10.1016/S0022-5347(05)65465-1, 11743353.
45. Yoo GH, Piechocki MP, Oliver J, Lonardo F, Zumstein L, Lin HS, Kim H, Shibuya TY, Shehadeh N, Ensley JF. Enhancement of Ad-p53 therapy with docetaxel in head and neck cancer. Laryngoscope 2004, 114:1871-1879. 10.1097/01.mlg.0000147914.51239.ed, 15510008.
46. Johnson SW, Stevenson JP, O'Dwyer VT. Cisplatin and its analogues. Cancer: Principles and Practice of Oncology 2001, 376-88. Philadelphia: Lippincott, Williams & Wilkins, DeVita VT, Hellman S, Rosenberg SA.
47. Vasey PA, Atkinson R, Coleman R, Crawford M, Cruickshank M, Eggleton P, Fleming D, Graham J, Parkin D, Paul J, et al. Docetaxel-carboplatin as first line chemotherapy for epithelial ovarian cancer. Br J Cancer 2001, 84:170-178. 10.1054/bjoc.2000.1572, 2363708, 11161372.
48. Chidgey M, Dawson C. Desmosomes: a role in cancer?. Br J Cancer 2007, 96:1783-1787. 10.1038/sj.bjc.6603808, 2359958, 17519903.